Short Interest in AstraZeneca PLC (OTCMKTS:AZNCF) Decreases By 69.5%

AstraZeneca PLC (OTCMKTS:AZNCF) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 58,800 shares, a decrease of 69.5% from the November 30th total of 192,900 shares. Based on an average daily volume of 6,300 shares, the days-to-cover ratio is presently 9.3 days.

AstraZeneca Trading Up -2.0 %

AZNCF traded up $0.88 on Friday, hitting $132.00. 2,601 shares of the company’s stock were exchanged, compared to its average volume of 2,728. AstraZeneca has a fifty-two week low of $118.16 and a fifty-two week high of $175.00. The firm has a 50-day moving average price of $135.09 and a 200-day moving average price of $150.64.

Institutional Investors Weigh In On AstraZeneca

A hedge fund recently bought a new stake in AstraZeneca stock. Eagle Bay Advisors LLC bought a new stake in AstraZeneca PLC (OTCMKTS:AZNCF) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 1,001 shares of the company’s stock, valued at approximately $156,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.